Moderna, Inc. Costs and Expenses
Moderna, Inc. (MRNA) reported Costs and Expenses of $960.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-31
- Moderna, Inc. costs and expenses for the quarter ending 2026-06-30 was $960.00M, a 8.48% decline year-over-year.
- Moderna, Inc. costs and expenses for the quarter ending 2026-03-31 was $1.78B, a 53.45% increase year-over-year.
- Moderna, Inc. costs and expenses for the quarter ending 2025-12-31 was $1.53B, a 30.61% decline year-over-year.
- Moderna, Inc. costs and expenses for the quarter ending 2025-09-30 was $1.28B, a 33.95% decline year-over-year.
- Moderna, Inc. costs and expenses for fiscal 2025 was $5.02B, a 30.12% decline from fiscal 2024.
- Moderna, Inc. costs and expenses for fiscal 2024 was $7.18B, a 35.23% decline from fiscal 2023.
- Moderna, Inc. costs and expenses for fiscal 2023 was $11.09B, a 12.64% increase from fiscal 2022.
- Moderna, Inc. costs and expenses for fiscal 2022 was $9.84B, a 90.20% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $960.00M 10-Q · filed 2026-07-31 | $2.74B 10-Q · filed 2026-07-31 | $4.27B derived: sum of 3 quarters · filed 2026-07-31 | $5.55B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2026-03-31 | $1.78B 10-Q · filed 2026-05-01 | $3.31B derived: sum of 2 quarters · filed 2026-05-01 | $4.59B derived: sum of 3 quarters · filed 2026-05-01 | $5.64B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-12-31 | $1.53B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.81B derived: sum of 2 quarters · filed 2026-02-20 | $3.86B derived: sum of 3 quarters · filed 2026-07-31 | $5.02B 10-K · filed 2026-02-20 | |
| 2025-09-30 | $1.28B 10-Q · filed 2025-11-06 | $2.33B derived: sum of 2 quarters · filed 2026-07-31 | $3.48B 10-Q · filed 2025-11-06 | $5.70B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-06-30 | $1.05B 10-Q · filed 2026-07-31 | $2.21B 10-Q · filed 2026-07-31 | $4.42B derived: sum of 3 quarters · filed 2026-07-31 | $6.35B derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $1.16B 10-Q · filed 2026-05-01 | $3.37B derived: sum of 2 quarters · filed 2026-05-01 | $5.30B derived: sum of 3 quarters · filed 2026-05-01 | $6.91B derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | $2.21B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $4.14B derived: sum of 2 quarters · filed 2026-02-20 | $5.75B derived: sum of 3 quarters · filed 2026-02-20 | $7.18B 10-K · filed 2026-02-20 | |
| 2024-09-30 | $1.93B 10-Q · filed 2025-11-06 | $3.54B derived: sum of 2 quarters · filed 2025-11-06 | $4.97B 10-Q · filed 2025-11-06 | $7.77B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-06-30 | $1.60B 10-Q · filed 2025-08-01 | $3.04B 10-Q · filed 2025-08-01 | $5.84B derived: sum of 3 quarters · filed 2026-02-20 | $9.69B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2024-03-31 | $1.43B 10-Q · filed 2025-05-01 | $4.24B derived: sum of 2 quarters · filed 2026-02-20 | $8.08B derived: sum of 3 quarters · filed 2026-02-20 | $10.29B derived: sum of 4 quarters · filed 2026-02-20 | |
| 2023-12-31 | $2.81B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $6.65B derived: sum of 2 quarters · filed 2026-02-20 | $8.86B derived: sum of 3 quarters · filed 2026-02-20 | $11.09B 10-K · filed 2026-02-20 | |
| 2023-09-30 | $3.84B 10-Q · filed 2024-11-07 | $6.05B derived: sum of 2 quarters · filed 2024-11-07 | $8.28B 10-Q · filed 2024-11-07 | $11.79B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-06-30 | $2.21B 10-Q · filed 2024-08-01 | $4.44B 10-Q · filed 2024-08-01 | $7.94B derived: sum of 3 quarters · filed 2025-02-21 | $10.14B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2023-03-31 | $2.23B 10-Q · filed 2024-05-02 | $5.73B derived: sum of 2 quarters · filed 2025-02-21 | $7.93B derived: sum of 3 quarters · filed 2025-02-21 | $10.23B derived: sum of 4 quarters · filed 2025-02-21 | |
| 2022-12-31 | $3.50B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $5.70B derived: sum of 2 quarters · filed 2025-02-21 | $8.00B derived: sum of 3 quarters · filed 2025-02-21 | $9.84B 10-K · filed 2025-02-21 | |
| 2022-09-30 | $2.20B 10-Q · filed 2023-11-03 | $4.50B derived: sum of 2 quarters · filed 2023-11-03 | $6.34B 10-Q · filed 2023-11-03 | $8.14B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | $2.30B 10-Q · filed 2023-08-03 | $4.14B 10-Q · filed 2023-08-03 | $5.94B derived: sum of 3 quarters · filed 2024-02-23 | $7.35B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $1.84B 10-Q · filed 2023-05-04 | $3.64B derived: sum of 2 quarters · filed 2024-02-23 | $5.05B derived: sum of 3 quarters · filed 2024-02-23 | $6.34B derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $1.80B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $3.21B derived: sum of 2 quarters · filed 2024-02-23 | $4.50B derived: sum of 3 quarters · filed 2024-02-23 | $5.17B 10-K · filed 2024-02-23 | |
| 2021-09-30 | $1.41B 10-Q · filed 2022-11-03 | $2.70B derived: sum of 2 quarters · filed 2022-11-03 | $3.37B 10-Q · filed 2022-11-03 | $4.22B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $1.29B 10-Q · filed 2022-08-03 | $1.96B 10-Q · filed 2022-08-03 | $2.81B derived: sum of 3 quarters · filed 2023-02-24 | $3.20B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $671.00M 10-Q · filed 2022-05-04 | $1.52B derived: sum of 2 quarters · filed 2023-02-24 | $1.91B derived: sum of 3 quarters · filed 2023-02-24 | $2.10B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $846.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $1.24B derived: sum of 2 quarters · filed 2023-02-24 | $1.43B derived: sum of 3 quarters · filed 2023-02-24 | $1.57B 10-K · filed 2023-02-24 | $1.57B 10-K · filed 2021-02-26 |
| 2020-09-30 | $392.00M 10-Q · filed 2021-11-04 | $581.00M derived: sum of 2 quarters · filed 2021-11-04 | $720.00M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $189.00M 10-Q · filed 2021-08-05 | $328.00M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $139.00M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $606.00M 10-K · filed 2022-02-25 | $605.93M 10-K · filed 2021-02-26 | |||
| 2018-12-31 | $548.33M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |